Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 6/20 | 0.50 |
| ▸ | ACACB | O00763 | 5/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.39 |
| ▸ | CDK2 | P24941 | 7/20 | 0.39 |
| ▸ | GSK3B | P49841 | 5/20 | 0.39 |
| ▸ | ELOC | Q15369 | 3/20 | 0.38 |
| ▸ | ELOB | Q15370 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26241389 | 0.84 | VHL (0.53) | VHLP2RX7CCNE1CDK2GSK3B | |
| SCHEMBL20012510 | 0.82 | VHL (0.51) | VHLP2RX7CCNE1CDK2GSK3B | |
| SCHEMBL21696439 | 0.79 | CCNE1 (0.54) | VHLCCNE1CDK2GSK3B | |
| SCHEMBL21696556 | 0.79 | CCNE1 (0.54) | VHLCCNE1CDK2GSK3B | |
| SCHEMBL21696706 | 0.77 | CCNE1 (0.54) | VHLCCNE1CDK2GSK3B | |
| SCHEMBL15112607 | 0.72 | VHL (0.55) | VHLP2RX7CCNE1CDK2GSK3B | |
| SCHEMBL20008989 | 0.71 | IDH1 (0.47) | — | |
| SCHEMBL24711724 | 0.71 | SMN1; SMN2 (0.44) | — | |
| SCHEMBL32661830 | 0.71 | VHL (0.51) | VHLP2RX7CCNE1CDK2GSK3B | |
| SCHEMBL21696674 | 0.70 | VHL (0.50) | VHLP2RX7CCNE1CDK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3262036-B1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | VHL 97/4885ACACB 3506/4885P2RX7 2563/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | VHL 97/4885ACACB 3506/4885P2RX7 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.